-
Mashup Score: 0New England - 1 month(s) ago
The North American Neuroendocrine Tumor Society (NANETS) offers comprehensive, accredited medical education programs on NET disease that are developed by leading NET experts and designed exclusively for medical professionals. We also provide research grants, travel grants and education grants to young investigators doing preeminent work in the field of NET research. Visit our website to learn how you can get involved or to make a donation today!
Source: nanets.netCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
When neuroendocrine tumors occur in the gastrointestinal tract, surgery can offer symptom relief and sometimes improve survival. Jessica Maxwell, M.D., shares what patients should know.
Source: www.mdanderson.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
If you have a neuroendocrine tumor in the gastrointestinal tract, how can surgery help? Our Dr. Jess Maxwell explains: https://t.co/HHuW4cRZ0Y #NeuroendocrineTumor #EndCancer
-
-
Mashup Score: 0NCAN 2023 San Diego NET Patient Conference - 1 year(s) ago
Please join us Saturday, June 3rd for the not-to-be-missed, in-person NCAN 2023 San Diego NET Patient Conference in San Diego, CA.
Categories: Hem/Oncs, Latest HeadlinesTweet-
We're under a month away from our NCAN NET Patient Conference in San Diego, CA! California friends join us. @SylvesterCancer @JaydiDelRivero @AGangiMD https://t.co/M8e2mA3zXV #NeuroendocrineCancer #NeuroendocrineTumor #NETs 🦓 https://t.co/wvF1cS3tk5
-
-
Mashup Score: 2Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor - 1 year(s) ago
von Hippel-Lindau (VHL) disease is a rare autosomal-dominant hereditary disease characterized by mutation of the VHL gene. This gene encodes for the VHL protein, which regulates the activity of HIF-α, a transcription factor involved in the cellular response to hypoxia. Mutations in VHL lead to the accumulation of HIF-α and, consequently, the engagement of hypoxia-sensitive genes with tumorigenic…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Case report by @pelle_eleonora, @altoubaht, Brian Morse, MD, and Jonathan Strosberg, MD, of @MoffittNews describes near-complete response to belzutifan in patient with VHL-associated metastatic pancreatic #neuroendocrinetumor: https://t.co/th7d99i9s7 #NeuroendocrineCancer #PNET https://t.co/hezQPVqnz9
-
-
Mashup Score: 8Pheochromocytoma survivor achieves remission through targeted therapy clinical trial - 2 year(s) ago
By the time Alabama resident Susan Waldrop was diagnosed with a rare neuroendocrine tumor called pheochromocytoma, she’d been suffering from symptoms for almost five years. At MD Anderson, surgery and a clinical trial put her in remission — and the clinical trial she participated in led to the first FDA approval of a drug to treat this rare disease.
Source: MD Anderson Cancer CenterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Susan Waldrop joined a clinical trial at MD Anderson that put her sporadic metastatic pheochromocytoma in remission. Read how our Dr. Camilo Jimenez gave her hope: https://t.co/nfTWFR7igc #NeuroendocrineTumor #EndCancer
-
-
Mashup Score: 2Stage IV neuroendocrine tumor survivor: Why I keep joining clinical trials at MD Anderson - 2 year(s) ago
The drug Kimberly Love received through a clinical trial at MD Anderson in 2008 became the same one that would help her again 14 years later, once the FDA approved it to treat neuroendocrine tumors.
Source: MD Anderson Cancer CenterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Thanks to MD Anderson’s research and expertise, Kimberly Love is able to manage a stage IV neuroendocrine tumor like a chronic disease. Here’s her story: https://t.co/TMLiE4HyQn #NeuroendocrineTumor #EndCancer
-
-
Mashup Score: 8Stage IV neuroendocrine tumor survivor: Why I keep joining clinical trials at MD Anderson - 2 year(s) ago
The drug Kimberly Love received through a clinical trial at MD Anderson in 2008 became the same one that would help her again 14 years later, once the FDA approved it to treat neuroendocrine tumors.
Source: MD Anderson Cancer CenterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
14 years ago, Kimberly Love enrolled in a clinical trial to treat a stage IV neuroendocrine tumor. Now, the drug is approved by the FDA and she’s still benefitting from it: https://t.co/y0ZPVTMtE5 #NeuroendocrineTumor #EndCancer
-
-
Mashup Score: 0The Cancer News Daily - 2 year(s) ago
The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Cancer News Daily! https://t.co/4PnERpxswB Thanks to @HopkinsMedicine #oncology #neuroendocrinetumor
-
-
Mashup Score: 3Neuroendocrine tumor survivor defies the odds - 2 year(s) ago
Curtis Crump was given six months to live after a neuroendocrine tumor diagnosis. Then he sought a second opinion from MD Anderson, where he participated in a clinical trial.
Source: MD Anderson Cancer CenterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“I was given six months to live. Then I came to MD Anderson, and look at me now,” says Curtis Crump, who is in remission after receiving a stage IV neuroendocrine tumor diagnosis: https://t.co/VtksKcr5Z1 #NeuroendocrineTumor #EndCancer
-
-
Mashup Score: 1Young Woman’s Back Pain Turns out to Be Rare Tumor - 2 year(s) ago
Share with friendsChyna Woods was like many people during the pandemic — busy working from home and caring for her grandmother — until pain between her shoulder blades made sitting in her desk chair unbearable. “I had extremely excruciating back pain. I couldn’t lay or sit down for long periods of time,” says Woods. “I couldn’t even […]
Categories: Latest Headlines, Oncologists1Tweet-
RT @CarcinoidNETs: Young Woman's Back Pain Turns out to Be Rare #NeuroendocrineTumor- a #paraganglioma https://t.co/Tl8U7mcWQg #pheo #para…
-
Join Dana-Farber's Dr. Jennifer Chan as she co-hosts the @NANETS1 Multidisciplinary Management of NET Disease Medical Education Conference for health professionals on Saturday, May 4 7:30 am-3:30 pm. Learn more and register here: https://t.co/7vw52Mp94r #neuroendocrinetumor https://t.co/J759Vy9GE4